346 related articles for article (PubMed ID: 21922382)
21. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
22. mTOR inhibitors and sorafenib for recurrent heptocellular carcinoma after orthotopic liver transplantation.
Waidmann O; Hofmann WP; Zeuzem S; Trojan J
J Hepatol; 2011 Feb; 54(2):396-8. PubMed ID: 21111506
[No Abstract] [Full Text] [Related]
23. Sorafenib, a systemic therapy for hepatocellular carcinoma.
Méndez-Sánchez N; Vásquez-Fernández F; Zamora-Valdés D; Uribe M
Ann Hepatol; 2008; 7(1):46-51. PubMed ID: 18376365
[TBL] [Abstract][Full Text] [Related]
24. Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.
Hagiwara S; Kudo M; Nagai T; Inoue T; Ueshima K; Nishida N; Watanabe T; Sakurai T
Br J Cancer; 2012 Jun; 106(12):1997-2003. PubMed ID: 22596232
[TBL] [Abstract][Full Text] [Related]
25. [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC].
Greten TF; Manns MP; Malek N
Z Gastroenterol; 2009 Jan; 47(1):55-60. PubMed ID: 19156592
[TBL] [Abstract][Full Text] [Related]
26. Sorafenib: complexities of Raf-dependent and Raf-independent signaling are now unveiled.
Matsuda Y; Fukumoto M
Med Mol Morphol; 2011 Dec; 44(4):183-9. PubMed ID: 22179180
[TBL] [Abstract][Full Text] [Related]
27. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
28. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era.
Pfiffer TE; Seehofer D; Nicolaou A; Neuhaus R; Riess H; Trappe RU
Tumori; 2011; 97(4):436-41. PubMed ID: 21989430
[TBL] [Abstract][Full Text] [Related]
29. Sorafenib for hepatocellular carcinoma patients beyond Milan criteria after orthotopic liver transplantation: a case control study.
Teng CL; Hwang WL; Chen YJ; Chang KH; Cheng SB
World J Surg Oncol; 2012 Feb; 10():41. PubMed ID: 22339891
[TBL] [Abstract][Full Text] [Related]
30. Aurora kinase inhibitor PHA-739358 suppresses growth of hepatocellular carcinoma in vitro and in a xenograft mouse model.
Benten D; Keller G; Quaas A; Schrader J; Gontarewicz A; Balabanov S; Braig M; Wege H; Moll J; Lohse AW; Brummendorf TH
Neoplasia; 2009 Sep; 11(9):934-44. PubMed ID: 19724687
[TBL] [Abstract][Full Text] [Related]
31. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
Fujiki M; Aucejo F; Kim R
Clin Transplant; 2013; 27(2):169-77. PubMed ID: 23216662
[TBL] [Abstract][Full Text] [Related]
32. Vitamin K enhancement of sorafenib-mediated HCC cell growth inhibition in vitro and in vivo.
Wei G; Wang M; Hyslop T; Wang Z; Carr BI
Int J Cancer; 2010 Dec; 127(12):2949-58. PubMed ID: 21351273
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib suppresses postsurgical recurrence and metastasis of hepatocellular carcinoma in an orthotopic mouse model.
Feng YX; Wang T; Deng YZ; Yang P; Li JJ; Guan DX; Yao F; Zhu YQ; Qin Y; Wang H; Li N; Wu MC; Wang HY; Wang XF; Cheng SQ; Xie D
Hepatology; 2011 Feb; 53(2):483-92. PubMed ID: 21274870
[TBL] [Abstract][Full Text] [Related]
34. Current status of hepatocellular carcinoma treatment in Japan: case study and discussion-voting system.
Kudo M; Tateishi R; Yamashita T; Ikeda M; Furuse J; Ikeda K; Kokudo N; Izumi N; Matsui O
Clin Drug Investig; 2012 Aug; 32 Suppl 2():37-51. PubMed ID: 22873626
[TBL] [Abstract][Full Text] [Related]
35. Metformin sensitizes sorafenib to inhibit postoperative recurrence and metastasis of hepatocellular carcinoma in orthotopic mouse models.
You A; Cao M; Guo Z; Zuo B; Gao J; Zhou H; Li H; Cui Y; Fang F; Zhang W; Song T; Li Q; Zhu X; Yin H; Sun H; Zhang T
J Hematol Oncol; 2016 Mar; 9():20. PubMed ID: 26957312
[TBL] [Abstract][Full Text] [Related]
36. Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
Saidi RF; Shah SA; Rawson AP; Grossman S; Piperdi B; Bozorgzadeh A
Transplant Proc; 2010 Dec; 42(10):4582-4. PubMed ID: 21168742
[TBL] [Abstract][Full Text] [Related]
37. Feasibility of (125)I brachytherapy combined with sorafenib treatment in patients with multiple lung metastases after liver transplantation for hepatocellular carcinoma.
Li C; Zhang F; Zhang W; Zhang L; Huang Z; Wu P
J Cancer Res Clin Oncol; 2010 Nov; 136(11):1633-40. PubMed ID: 20865361
[TBL] [Abstract][Full Text] [Related]
38. Antitumor effect of sorafenib and mammalian target of rapamycin inhibitor in liver transplantation recipients with hepatocellular carcinoma recurrence.
Jung DH; Tak E; Hwang S; Song GW; Ahn CS; Kim KH; Moon DB; Ha TY; Park GC; Ryoo BY; Lee KJ; Kim N; Kwon JH; Jwa EK; Lee SG
Liver Transpl; 2018 Jul; 24(7):932-945. PubMed ID: 29710388
[TBL] [Abstract][Full Text] [Related]
39. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation.
TAN WF; Qiu ZQ; YU Y; RAN RZ; YI B; LAU WY; LIU C; QIU YH; FENG FL; WANG JH; YAN PN; ZHANG BH; WU MC; LUO XJ; JIANG XQ
Acta Pharmacol Sin; 2010 Dec; 31(12):1643-8. PubMed ID: 21102481
[TBL] [Abstract][Full Text] [Related]
40. [Our experience of the treatment with sorafenib for unresectable hepatocellular carcinoma].
Ishizaki M; Kaibori M; Matsui K; Nakatake R; Matsushima H; Sakaguchi T; Kwon AH
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2493-5. PubMed ID: 22202424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]